SG11201405686PA - Treatment of cancer with tor kinase inhibitors - Google Patents

Treatment of cancer with tor kinase inhibitors

Info

Publication number
SG11201405686PA
SG11201405686PA SG11201405686PA SG11201405686PA SG11201405686PA SG 11201405686P A SG11201405686P A SG 11201405686PA SG 11201405686P A SG11201405686P A SG 11201405686PA SG 11201405686P A SG11201405686P A SG 11201405686PA SG 11201405686P A SG11201405686P A SG 11201405686PA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
kinase inhibitors
tor kinase
tor
Prior art date
Application number
SG11201405686PA
Inventor
Shuichan Xu
Kristen Mae Hege
Heather Raymon
Toshiya Tsuji
Lisa Sapinoso
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of SG11201405686PA publication Critical patent/SG11201405686PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
SG11201405686PA 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors SG11201405686PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611428P 2012-03-15 2012-03-15
US201261715327P 2012-10-18 2012-10-18
PCT/US2013/031217 WO2013138560A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201405686PA true SG11201405686PA (en) 2014-10-30

Family

ID=48045717

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405686PA SG11201405686PA (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Country Status (22)

Country Link
US (1) US20130245028A1 (en)
EP (1) EP2825171B1 (en)
JP (2) JP2015511964A (en)
KR (1) KR102057357B1 (en)
CN (2) CN109846884A (en)
AU (2) AU2013202992B2 (en)
BR (1) BR112014022700A2 (en)
CA (1) CA2867174C (en)
EA (1) EA028062B1 (en)
ES (1) ES2668279T3 (en)
HK (1) HK1202247A1 (en)
IL (1) IL234639B (en)
MX (1) MX359227B (en)
MY (1) MY198666A (en)
NI (1) NI201400110A (en)
NZ (1) NZ628420A (en)
PH (1) PH12014502047B1 (en)
SG (1) SG11201405686PA (en)
TW (1) TWI622395B (en)
UA (1) UA114194C2 (en)
WO (1) WO2013138560A1 (en)
ZA (1) ZA201406708B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AR094494A1 (en) 2013-01-16 2015-08-05 Signal Pharm Llc REPLACED PIRROLOPIRIMIDINS, THEIR COMPOSITIONS, AND THEIR TREATMENT METHODS
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
US9359364B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
WO2014172426A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
SG10201708111YA (en) * 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CA2912627C (en) 2013-05-29 2022-03-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JP2017514806A (en) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ,エルエルシー Methods of treating cancer using TOR kinase inhibitor combination therapy
JP2017520603A (en) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ,エルエルシー Method for treating cancer using substituted pyrrolopyrimidine compound and composition thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3313403A4 (en) * 2015-06-24 2019-02-20 Celgene Corporation Treatment of cancer with dnapk inhibitors
US11318139B2 (en) 2016-01-26 2022-05-03 Dana-Farber Cancer Institute, Inc. Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents
BR112019027402A2 (en) 2017-06-22 2020-07-07 Celgene Corporation treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457913B1 (en) * 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
EP2078018B1 (en) 2006-10-19 2012-03-14 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2010004863A1 (en) * 2008-07-10 2010-01-14 日鉱金属株式会社 Hybrid silicon wafer and method for manufacturing same
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP2012509058A (en) * 2008-11-20 2012-04-19 オンコセラピー・サイエンス株式会社 Methods for diagnosing or treating prostate cancer
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
AR078793A1 (en) * 2009-10-27 2011-12-07 Orion Corp DERIVATIVES OF NON-STEROID CARBOXAMIDS AND ACIL HYDRAZONE MODULATORS OF ANDROGENIC RECEPTORS OF SELECTIVE FABRIC (SARM), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF PROSTATE CANCER BETWEEN OTHERS

Also Published As

Publication number Publication date
EA028062B1 (en) 2017-10-31
JP2015511964A (en) 2015-04-23
AU2015213353B2 (en) 2017-07-27
PH12014502047A1 (en) 2014-12-10
KR102057357B1 (en) 2019-12-18
ZA201406708B (en) 2016-05-25
PH12014502047B1 (en) 2014-12-10
JP6470822B2 (en) 2019-02-13
EA201491701A1 (en) 2015-01-30
MX2014011116A (en) 2015-04-08
AU2015213353A1 (en) 2015-09-03
KR20140138928A (en) 2014-12-04
ES2668279T3 (en) 2018-05-17
US20130245028A1 (en) 2013-09-19
TW201343166A (en) 2013-11-01
CA2867174A1 (en) 2013-09-19
BR112014022700A2 (en) 2020-06-30
WO2013138560A1 (en) 2013-09-19
IL234639B (en) 2020-05-31
CN104271138A (en) 2015-01-07
HK1202247A1 (en) 2015-09-25
AU2013202992A1 (en) 2013-10-03
TWI622395B (en) 2018-05-01
NI201400110A (en) 2015-01-12
NZ628420A (en) 2016-04-29
CA2867174C (en) 2020-06-23
MY198666A (en) 2023-09-14
CN109846884A (en) 2019-06-07
IL234639A0 (en) 2014-11-30
EP2825171A1 (en) 2015-01-21
JP2018058861A (en) 2018-04-12
AU2013202992B2 (en) 2015-09-03
EP2825171B1 (en) 2018-03-14
MX359227B (en) 2018-09-20
UA114194C2 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
IL274318A (en) Treatment of cancer with tor kinase inhibitors
HK1243919A1 (en) Treatment of cancer with tor kinase inhibitors
HK1202247A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1201750A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1220640A1 (en) Treatment of cancer with heterocyclic inhibitors of glutaminase
HK1201753A1 (en) Treatment of cancer with tor kinase inhibitors tor
ZA201503105B (en) Treatment of prostate cancer with tor kinase inhibitors
EP2903644A4 (en) Treatment of cancer
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
HK1205500A1 (en) Kinase inhibitors for the treatment of cancer
EP2897607A4 (en) Inhibitors of beta-hydrolase for treatment of cancer
GB201217890D0 (en) Treatment of cancer
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors
GB201208296D0 (en) Treatment of cancer